CinDome Pharma Announces $40 Million Series B Extension
CinDome Pharma Announces $40 Million Series B Extension
CinFina Pharma Announces FDA Clearance of Investigational New Drug Application and First Participants Dosed in Phase 1 Trial of CIN-110 for the Treatment of Obesity
CinFina Pharma Announces FDA Clearance of Investigational New Drug Application and First Participants Dosed in Phase 1 Trial of CIN-110 for the Treatment of Obesity
CinPhloro Pharma, A CinRx Portfolio Company, Dosed First Participant in Phase 2 enviva Study of CIN-103 for IBS-D
CinPhloro Pharma Dosed First Participant in Phase 2 enviva Study of CIN-103 for IBS-D.